PFD Capital Partners announced the launch of three new 2026 Special Purpose Entities—PFDSMR1017, PFDSMR2002, and PFDSMH3002—further expanding its medical accounts receivable specialty finance platform, including both personal injury–based receivables and a hybrid medical technology investment offering. These new offerings reflect PFD’s continued growth, disciplined underwriting approach, and commitment to building long-term relationships with medical providers and investors. The offerings are being made under Rule 506(c) and are limited to verified accredited investors, who are invited to begin the qualification process through a secure preliminary questionnaire before receiving additional investment materials.